EMEA completes antidepressant review

The EMEA said serotonin selective reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) should not be used in children and adolescents except for their approved indications. The agency reviewed 13 drugs, most of which are approved to treat depression and anxiety in adults in the EU but are not approved to treat these conditions in children. Among these, Strattera atomoxetine, an SNRI from Eli Lilly (LLY), also is approved to treat ADHD in children. In addition, some of the compounds are approved for pediatric obsessive-compulsive disorder. ...